SCHEMBL5337901

SCHEMBL5337901

CCC1CCN(CCn2cnc3ccccc32)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
LMNA P02545 5/20 0.57
HTT P42858 3/20 0.57
TSHR P16473 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
DRD2 P14416 3/20 0.55
SLC6A4 P31645 1/20 0.55
ADRA2A P08913 1/20 0.53
DRD4 P21917 2/20 0.51
DRD3 P35462 2/20 0.51
P2RX7 Q99572 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
EGLN3 Q9H6Z9 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
TNF P01375 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5337194 0.92 DRD2 (0.62) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5332092 0.90 LMNA (0.61) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5337843 0.87 LMNA (0.59) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5331681 0.86 TDP1 (0.63) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5338674 0.82 DRD2 (0.59) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5335283 0.81 DRD2 (0.58) TDP1LMNAHTTTSHRNPSR1
SCHEMBL18098557 0.80 TDP1 (0.71) TDP1LMNAHTTTSHRNPSR1
SCHEMBL11712309 0.79 TDP1 (0.69) TDP1LMNAHTTTSHRNPSR1
SCHEMBL6871616 0.79 TDP1 (0.69) TDP1LMNAHTTTSHRNPSR1
SCHEMBL5334924 0.78 DRD2 (0.64) TDP1LMNAHTTTSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US disclosed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP disclosed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US disclosed
US-6627645-B2 Cholinergic agents ACADIA PHARMACEUTICALS, INC. 2003-09-30 US disclosed
EP-1278741-A1 MUSCARINIC AGONISTS Acadia Pharmaceuticals Inc. (US) 2003-01-29 EP disclosed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US disclosed
WO-2001083472-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS, INC. (US) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037886-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 TDP1 2177/4885LMNA 1956/4885HTT 2280/4885
US-20070155795-A1 MUSCARINIC AGONISTS CHRM2, CHRM1, CHRM4 TDP1 2177/4885LMNA 1956/4885HTT 2280/4885
US-20050113357-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 TDP1 2177/4885LMNA 1956/4885HTT 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.